RealRate Inc., 2040 Martin Ave., Santa Clara, CA 95050

RealRate

July 10, 2026

To the CEO
Monopar Therapeutics
1000 SKOKIE BLVD SUITE 350
WILMETTE, IL 60091
USA

Monopar Therapeutics TOP Rated in the US Pharmaceutical Ranking

Dear Sir or Madam,

at RealRate we have just published the 2026 US Pharmaceutical ranking. I am happy to inform you that Monopar Therapeutics has been TOP Rated at rank 2 out of 178.

Overall, 178 US companies were analyzed with respect to their financial strength. The complete rating is published at https://www.realrate.ai/rankings. Your individual rating report, showing your strengths compared to your competitors is attached.

TOP RATED 2026 RealRate

Monopar Therapeutics

RealRate is an international rating agency based in Santa Clara and Berlin. We use artificial intelligence to create fair and explainable company ratings. Customers highly appreciate the RealRate rating seal: only the strongest companies are able to offer highly attractive and innovative products with top customer services. Billion dollar companies rely on our rating and build trust with their customers.

You too can acquire the RealRate seal and advertise with it. We only reach out to the top-rated companies, like yours and only those may subscribe for our seal. Save a lot of money and effort compared to traditional rating agencies: get a RealRate seal for just $9,900. Simply sign the attached order form and send it back via email.

Please feel free to book a short video call with me: https://calendly.com/holger-bartel

Sincerely,

Dr. Holger Bartel, CEO

holger.bartel@realrate.ai • www.realrate.ai • +49 160 957 90 844

RealRate Seal Subscription

RealRate Inc.
2040 Martin Ave., Santa Clara, California 95050, USA
Via email to: holger.bartel@realrate.ai

We subscribe to the Pharmaceutical RealRate rating for Monopar Therapeutics. The subscription comprises the annual rating update. The invoice will be sent annually, provided that a TOP rating is achieved again. The subscription can be cancelled by written letter, effective for the following year.

RealRate provides the rating seal as a scalable vector graphic. It can be used without any restrictions by Monopar Therapeutics (Customer) for all promotional purposes, i.e. in product brochures, presentations, websites and broadcasting.

Item	**2026 US Pharmaceutical RealRate rating seal for Monopar Therapeutics**
Amount	**USD 9,900**
Order no.	2026-0001645469

Amounts payable by Customer are exclusive of taxes. Customer is responsible for all his taxes and will pay such amounts invoiced by RealRate.

Billing address

Company name		Full name	
Street address		Department	
City		Phone number	
State / provice		Email address	
ZIP code			
Country			

Shipping address
The electronic RealRate rating seal and the invoice will be sent to

Delivery email	

Monopar Therapeutics

Date, location, name

PHARMACEUTICAL 2026

Monopar Therapeutics
Rank 2 of 178



PHARMACEUTICAL 2026

Monopar Therapeutics
Rank 2 of 178

Monopar Therapeutics

The relative strengths and weaknesses of Monopar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Monopar Therapeutics compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 223% points.The greatest weakness of Monopar Therapeutics is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 439%, being 209% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	140,463
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,735
Liabilities, Non-Current	155
Other Assets	255
Other Compr. Net Income	95
Other Expenses	0
Other Liabilities	0
Other Net Income	2,988
Other Revenues	0
Property and Equipment	0
Research and Development	9,904
Selling, General and Administrative Expense	6,800

Output Variable	Value in 1000 USD
Assets	140,718
Liabilities	2,890
Expenses	16,704
Revenues	0
Stockholders Equity	137,828
Net Income	-13,717
Comprehensive Net Income	-13,669
BaseVar	81,698
ECR before LimitedLiability	399%
Economic Capital Ratio	439%